PTO/SB/08B (08-03)

Approved for use through 07/31/06. OMB 0651-0031
Under the Paperwork Resident of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Col	Complete if Known			
Application Number	09/155,590			
Filing Date	September 30, 1998			
First Named Inventor	Jeffrey SCHLOM et al.			
Art Unit	1643			
Examiner Name	CANELLA, Karen A.			
Attorney Docket	38163-0061			
Number				
<b>y</b>	Application Number  Filing Date  First Named Inventor  Art Unit  Examiner Name  Attorney Docket			

NON PATENT LITERATURE DOCUMENTS							
		Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
KAC B01			Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 2005;23:5099-107.				
		B02	Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-25.				
		B03	Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.				
		B04	Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64.				
		B05	Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.				
V		B06	Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.				

Examiner	1	<i>61</i> .	$\overline{\Lambda}$			./			Date	3			1	-/-	
Signature	1/1	run	11.	[ill	nli	L	 		Con	sidered	1	5/	15)	10 E	7
4534444455	14/ 1 10		7/	7			 	-			_				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not/in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

PTO/SB/08B (08-03)

Approved for use through 07/31/06. OMB 0651-0031
Under the Paperwork Reduction and the Paperwork Reduction of information unless it contains a valid OMB control number.

Substitute for form	1449/PTO		Complete if Known				
			Application Number	09/155,590			
INFORMATIO STATEMENT			Filing Date	September 30, 1998			
			First Named Inventor	Jeffrey SCHLOM et al.			
			Art Unit	1643			
(Use as ma	iny sheets as	necessary)	Examiner Name	CANELLA, Karen A.			
Sheet 2	of	2	Attorney Docket Number	38163-0061			

		NON PATENT LITERATURE DOCUMENTS						
Examiner initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc date, page(s), volume-issue number(s), publisher, city and/or country where publisher						
KAC	B07	Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.						
	B08	Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.						
	B09	Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-89.						
	B10	Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol. 1996;23:118-34.						
	B11	Fossum B, Gedde-Dahl I, T., Breivik J et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly>Asp). Int. J. Cancer 1994;56:40-5.						
	B12	Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol 2001;21:287-97.						
	B13	Linard B, Bezieau S, Benlalam H et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 2002;168:4802-8.						

		<u> </u>		
Examiner	11. // /9	. //	Date	-1-11
Signature ///	WILL II LIW	nell	Considered	5/13/00
	70/ V 77.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public